Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
BioDrugs
; 35(4): 429-444, 2021 Jul.
Article
in En
| MEDLINE
| ID: mdl-33914256
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Biosimilar Pharmaceuticals
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Year:
2021
Type:
Article